NHI 2

Key Product Details

Product Description

NHI 2 is an LDHA inhibitor; reduces lactate production in HeLa cells. Inhibits cell growth of LPC006 and PANC-1 cells in vitro. Enhances the antiproliferative effects of Gemcitabine (Cat. No. 3259) on LPC006 and PANC-1 cells. Also inhibits ferroptosis.

Product Specifications for NHI 2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for NHI 2

The following data is based on the product molecular weight 335.28.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.98 mL	14.91 mL	29.83 mL
5 mM	0.60 mL	2.98 mL	5.97 mL
10 mM	0.30 mL	1.49 mL	2.98 mL
50 mM	0.06 mL	0.30 mL	0.60 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 3 publications citing the usage of this product.

• Jacobsen APD-containing cyclolipodepsipeptides target mitochondrial function in hypoxic cancer cells. Cell Chem.Biol. 2018 PMID: 30122371
• Calvaresi Dual targeting of the Warburg effect with a glucose-conjugated lactate dehydrogenase inhibitor. Chembiochem 2013 PMID: 24174263
• Granchi Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. Org.Biomol.Chem. 2013 PMID: 23986182
• Maftouh Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcit. against pancreatic cancer cells in hypoxia. Br.J.Cancer 2014 PMID: 24178759

Product Documents for NHI 2